

Authorized Distributors

The following distributors are authorized to sell ONUREG® and are able to service qualified accounts.

Authorized Distributor Network

Physician Offices

Cardinal Health Specialty Pharmaceutical Distribution

Phone: 1-877-453-3972, Monday-Friday, 7:00am-6:00pm CT (24-hour emergency on call)
<https://specialtyonline.cardinalhealth.com/>

CuraScript Specialty Distribution

Phone: 1-877-599-7748, Monday-Friday, 8:00am-7:00pm ET | <https://www.curascripts.com>

McKesson Specialty Health

Phone: 1-800-482-6700, Monday-Friday, 7:00am-7:00pm CT | <https://mscs.mckesson.com>

Oncology Supply

Phone: 1-800-633-7555, Monday-Friday, 8:00am-7:00pm CT | <https://oncologysupply.com>

Hospitals and Infusion Centers

ASD Healthcare

Phone: 1-800-746-6273, Monday-Thursday, 7:00am-6:30pm CT; Friday, 7:00am-6:00pm CT
Fax: 1-800-547-9413 | <https://www.asdhealthcare.com>

Cardinal Health Specialty Pharmaceutical Distribution

Phone: 1-866-677-4844, Monday-Friday, 7:00am-6:00pm CT (24 hour emergency)
Fax: 1-614-553-6301 | <https://orderexpress.cardinalhealth.com>

McKesson Plasma and Biologics

Phone: 1-877-625-2566, Monday-Friday 8:00am-6:30pm CT | Fax: 1-888-752-7626
<https://connect.mckesson.com>

Puerto Rico Hospitals and Clinics

Cardinal Puerto Rico (Borschow)

Phone: 1-787-625-4200 | cuserv@cardinalhealth.com
Online ordering: <https://orderexpress.cardinalhealth.com>

Cesar Castillo Inc

Phone: 1-787-641-5242 (Hospitals) | 1-787-641-5082 (Specialty Pharmacy) | Fax: 1-787-999-1614
Online ordering: <https://www.facilfarmaciacci.com/>

If you have any questions about procurement, coverage, or reimbursement of ONUREG®, please contact BMS Access Support®.

Billing and Coding

AML ICD-10-CM DIAGNOSIS CODES^a

ICD-10-CM code	Descriptor
C92.00	Acute myeloblastic leukemia, not having achieved remission
C92.01	Acute myeloblastic leukemia, in remission
C92.50	Acute myelomonocytic leukemia, not having achieved remission
C92.51	Acute myelomonocytic leukemia, in remission
C92.60	Acute myeloid leukemia with 11q23-abnormality, not having achieved remission
C92.61	Acute myeloid leukemia with 11q23-abnormality, in remission
C92.A0	Acute myeloid leukemia with multilineage dysplasia, not having achieved remission
C92.A1	Acute myeloid leukemia with multilineage dysplasia, in remission
C92.Z0	Other myeloid leukemia, not having achieved remission
C92.Z1	Other myeloid leukemia, in remission
C92.90	Myeloid leukemia, unspecified, not having achieved remission
C92.91	Myeloid leukemia, unspecified, in remission
C93.00	Acute monoblastic/monocytic leukemia, not having achieved remission
C93.01	Acute monoblastic/monocytic leukemia, in remission
C94.00	Acute erythroid leukemia, not having achieved remission
C94.01	Acute erythroid leukemia, in remission
C94.20	Acute megakaryoblastic leukemia, not having achieved remission
C94.21	Acute megakaryoblastic leukemia, in remission

^aThis list may not be all-inclusive.

NATIONAL DRUG CODES (NDC) AND PACKAGING INFORMATION

Tablet strength	Package configuration	10-digit NDC	11-digit NDC ^a
200 mg	One blister card containing 7 tablets	59572-730-07	59572-0730-07
300 mg	One blister card containing 7 tablets	59572-740-07	59572-0740-07

^aPayer requirements regarding the use of NDCs may vary. Electronic data exchange generally requires use of the 11-digit NDC.

The information contained herein is not intended to provide specific coding and reimbursement advice for any specific patient or situation. You should check with your coding specialist to ensure appropriate submissions.

Abbreviations: AML, acute myeloid leukemia; ICD-10, *International Classification of Diseases*, Tenth Revision, Clinical Modification.

Please see Important Safety Information on page 5 and full Prescribing Information.

 **ONUREG**[™]
(azacitidine) tablets
300mg+200mg

Product Information

INDICATION

ONUREG® is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy.

HOW SUPPLIED

- 200 mg: pink, oval, film-coated tablets with debossed "200" on one side and "ONU" on the other side
- 300 mg: brown, oval, film-coated tablets with debossed "300" on one side and "ONU" on the other side

STORAGE

Store blisters at 20°C to 25°C (68°F to 77°F)

- Excursions permitted between 15°C to 30°C (59°F to 86°F)
- Store in the original aluminum-aluminum blisters



HANDLING AND DISPOSAL

ONUREG® is a hazardous drug. Follow applicable special handling and disposal procedures.* If powder comes in contact with skin, immediately and thoroughly wash with soap and water. If powder comes in contact with mucous membranes, immediately flush the area with water.

Selected Important Safety Information

CONTRAINDICATIONS

ONUREG® is contraindicated in patients with known severe hypersensitivity to azacitidine or its components.

WARNINGS AND PRECAUTIONS

Risks of Substitution with Other Azacitidine Products

Due to substantial differences in the pharmacokinetic parameters, the recommended dose and schedule for ONUREG® are different from those for the intravenous or subcutaneous azacitidine products. Treatment of patients using intravenous or subcutaneous azacitidine at the recommended dosage of ONUREG® may result in a fatal adverse reaction. Treatment with ONUREG® at the doses recommended for intravenous or subcutaneous azacitidine may not be effective. Do not substitute ONUREG® for intravenous or subcutaneous azacitidine.

Myelosuppression

New or worsening Grade 3 or 4 neutropenia and thrombocytopenia occurred in 49% and 22% of patients who received ONUREG®. Febrile neutropenia occurred in 12%. A dose reduction was required for 7% and 2% of patients due to neutropenia and thrombocytopenia. Less than 1% of patients discontinued ONUREG® due to either neutropenia or thrombocytopenia. Monitor complete blood counts and modify the dosage as recommended. Provide standard supportive care, including hematopoietic growth factors, if myelosuppression occurs.

Increased Early Mortality in Patients with Myelodysplastic Syndromes (MDS)

In AZA-MDS-003, 216 patients with red blood cell transfusion-dependent anemia and thrombocytopenia due to MDS were randomized to ONUREG® or placebo. 107 received a median of 5 cycles of ONUREG® 300 mg daily for 21 days of a 28-day cycle. Enrollment was discontinued early due to a higher incidence of early fatal and/or serious adverse reactions in the ONUREG® arm compared with placebo. The most frequent fatal adverse reaction was sepsis. Safety and effectiveness of ONUREG® for MDS have not been established. Treatment of MDS with ONUREG® is not recommended outside of controlled trials.

*Occupational Safety and Health Administration (OSHA). *OSHA Hazardous Drugs*.
<http://www.osha.gov/SLTC/hazardousdrugs/index.html>.

Please see Important Safety Information on page 5 and full Prescribing Information.

 **ONUREG**[™]
(azacitidine) tablets
300 mg + 200 mg

BMS Access Support® Can Provide Patient Access and Reimbursement Assistance

Bristol Myers Squibb is committed to helping patients gain access to their prescribed BMS medications. That's why we offer BMS Access Support. BMS Access Support provides resources to help patients understand their insurance coverage. In addition, we can share information on sources of financial support, including co-pay assistance for eligible commercially insured patients.



How BMS Access Support May Help

Find out how BMS can work with patients and their healthcare providers to help access a prescribed BMS medication.



Financial Support Options

There may be programs and services that could help with the cost of treatment. Learn about what options are available.



Additional Resources

We provide videos, tools, and other resources that may help with your access and reimbursement needs.

Have Questions About Our Program or Possible Financial Support?

If you have questions about coverage for a prescribed BMS medication, BMS Access Support may be able to help. Patients and their healthcare provider can complete an enrollment form to learn about programs that may be of assistance. Visit our website or contact BMS Access Support to learn more.



Call Bristol Myers Squibb Access Support at **1-800-861-0048**, 8 AM to 8 PM ET, Monday–Friday



Visit www.BMSAccessSupport.com

The accurate completion of reimbursement- or coverage-related documentation is the responsibility of the healthcare provider and the patient. Bristol Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item.

Indication

ONUREG® is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy.

Important Safety Information

CONTRAINDICATIONS

ONUREG® is contraindicated in patients with known severe hypersensitivity to azacitidine or its components.

WARNINGS AND PRECAUTIONS

Risks of Substitution with Other Azacitidine Products

Due to substantial differences in the pharmacokinetic parameters, the recommended dose and schedule for ONUREG® are different from those for the intravenous or subcutaneous azacitidine products. Treatment of patients using intravenous or subcutaneous azacitidine at the recommended dosage of ONUREG® may result in a fatal adverse reaction. Treatment with ONUREG® at the doses recommended for intravenous or subcutaneous azacitidine may not be effective. Do not substitute ONUREG® for intravenous or subcutaneous azacitidine.

Myelosuppression

New or worsening Grade 3 or 4 neutropenia and thrombocytopenia occurred in 49% and 22% of patients who received ONUREG®. Febrile neutropenia occurred in 12%. A dose reduction was required for 7% and 2% of patients due to neutropenia and thrombocytopenia. Less than 1% of patients discontinued ONUREG® due to either neutropenia or thrombocytopenia. Monitor complete blood counts and modify the dosage as recommended. Provide standard supportive care, including hematopoietic growth factors, if myelosuppression occurs.

Increased Early Mortality in Patients with Myelodysplastic Syndromes (MDS)

In AZA-MDS-003, 216 patients with red blood cell transfusion-dependent anemia and thrombocytopenia due to MDS were randomized to ONUREG® or placebo. 107 received a median of 5 cycles of ONUREG® 300 mg daily for 21 days of a 28-day cycle. Enrollment was discontinued early due to a higher incidence of early fatal and/or serious adverse reactions in the ONUREG® arm compared with placebo. The most frequent fatal adverse reaction was sepsis. Safety and effectiveness of ONUREG® for MDS have not been established. Treatment of MDS with ONUREG® is not recommended outside of controlled trials.

Embryo-Fetal Toxicity

ONUREG® can cause fetal harm when administered to a pregnant woman. Azacitidine caused fetal death and anomalies in pregnant rats via a single intraperitoneal dose less than the recommended human daily dose of oral azacitidine on a mg/m² basis. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with ONUREG® and for at least 6 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with ONUREG® and for at least 3 months after the last dose.

ADVERSE REACTIONS

Serious adverse reactions occurred in 15% of patients who received ONUREG®. Serious adverse reactions in ≥2% included pneumonia (8%) and febrile neutropenia (7%). One fatal adverse reaction (sepsis) occurred in a patient who received ONUREG®.

Most common (≥10%) adverse reactions with ONUREG® vs placebo were nausea (65%, 24%), vomiting (60%, 10%), diarrhea (50%, 21%), fatigue/asthenia (44%, 25%), constipation (39%, 24%), pneumonia (27%, 17%), abdominal pain (22%, 13%), arthralgia (14%, 10%), decreased appetite (13%, 6%), febrile neutropenia (12%, 8%), dizziness (11%, 9%), pain in extremity (11%, 5%).

LACTATION

There are no data regarding the presence of azacitidine in human milk or the effects on the breastfed child or milk production. Because of the potential for serious adverse reactions in the breastfed child, advise women not to breastfeed during treatment with ONUREG® and for 1 week after the last dose.

Please see full [Prescribing Information for ONUREG®](#).

